Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Share-based Compensation (2016 - 2025)

Moleculin Biotech's Share-based Compensation history spans 10 years, with the latest figure at $459000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $459000.0 for Q4 2025, up 7.49% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (down 3.59% YoY), and the annual figure for FY2025 was $1.7 million, down 3.59%.
  • Share-based Compensation for Q4 2025 was $459000.0 at Moleculin Biotech, up from $303000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $977000.0 in Q3 2021 to a low of $303000.0 in Q3 2025.
  • The 5-year median for Share-based Compensation is $489000.0 (2023), against an average of $501000.0.
  • The sharpest move saw Share-based Compensation surged 112.39% in 2021, then decreased 29.47% in 2023.
  • Year by year, Share-based Compensation stood at $556000.0 in 2021, then fell by 3.78% to $535000.0 in 2022, then decreased by 10.47% to $479000.0 in 2023, then decreased by 10.86% to $427000.0 in 2024, then increased by 7.49% to $459000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $459000.0, $303000.0, and $417000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.